Sample solution is provided at 25 µL, 10mM.
Publications citing ApexBio Products
|Cas No.||161832-65-1||SDF||Download SDF|
|Solubility||Soluble in DMSO||Storage||Store at -20°C|
Talampanel (LY300164) is a non-competitive antagonist of AMPA-receptor   .
The α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPA receptor) is a ionotropic transmembrane receptor for glutamate, which is involved in fast synaptic transmission in the central nervous system (CNS) .
Talampanel (LY300164) is a non-competitive AMPA-receptor antagonist. In primary rat hippocampal cultures, LY300164 dose-dependently attenuated kainic acid (KA)-excitotoxicity with IC50 value of 4 μM .
In male Mongolian gerbils with bilateral carotid artery occlusion, LY300164 (10 mg/kg) orally administration reduced responses to AMPA by 68% but reduced responses to NMDA only by 9%. LY300164 (10 mg/kg) administered orally or intravenously immediately after the occlusion exhibited good protection with 24% and 20% of the neurones surviving, respectively . In mice with transient focal cerebral ischemia/reperfusion, talampanel significantly reduced the infarct size by 33.1%. Also, talampanel significantly reduced the amount of TUNEL-positive cells and caspase-3 active cells .
. Lodge D, Bond A, O'Neill MJ, et al. Stereoselective effects-of 2,3-benzodiazepines in vivo: electrophysiology and neuroprotection studies. Neuropharmacology, 1996, 35(12): 1681-1688.
. May PC, Robison PM, Fuson KS. Stereoselective neuroprotection by novel 2,3-benzodiazepine non-competitive AMPA antagonist against non-NMDA receptor-mediated excitotoxicity in primary rat hippocampal cultures. Neurosci Lett, 1999, 262(3): 219-221.
. Denes L, Szilágyi G, Gál A, et al. Talampanel a non-competitive AMPA-antagonist attenuates caspase-3 dependent apoptosis in mouse brain after transient focal cerebral ischemia. Brain Res Bull, 2006, 70(3): 260-262.